Louisiana SB43 establishes the Psychedelic-Assisted Therapy Program within the Louisiana Department of Health.

Louisiana SB43 creates the Psychedelic-Assisted Therapy Program within the Louisiana Department of Health, aimed at facilitating clinical studies for psychedelic-assisted therapy. The program will focus on using psychedelic medications like ibogaine and psilocybin to treat opioid use disorders, co-occurring substance use disorders, and treatment-resistant neurological or mental health conditions. The Department of Health will approve academic health centers to participate in the program, provided they meet specific criteria including compliance with state and federal regulations.

Louisiana SB43 establishes the Psychedelic-Assisted Therapy Program within the Louisiana Department of Health.

Louisiana SB43 creates the Psychedelic-Assisted Therapy Program within the Louisiana Department of Health, aimed at facilitating clinical studies for psychedelic-assisted therapy. The program will focus on using psychedelic medications like ibogaine and psilocybin to treat opioid use disorders, co-occurring substance use disorders, and treatment-resistant neurological or mental health conditions. The Department of Health will approve academic health centers to participate in the program, provided they meet specific criteria including compliance with state and federal regulations.